Topics

Axsome gets exclusive US rights to reboxetine and esreboxetine from Pfizer

14:40 EST 15 Jan 2020 | Elsevier Business Intelligence

Pfizer Inc. licensed Axsome Therapeutics exclusive US rights to nonclinical and clinical data, and intellectual property surr...

Original Article: Axsome gets exclusive US rights to reboxetine and esreboxetine from Pfizer

NEXT ARTICLE

More From BioPortfolio on "Axsome gets exclusive US rights to reboxetine and esreboxetine from Pfizer"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Sleep Disorders
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...